Inosine: Parkinson's Disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects movement. The drug Inosine is proposed to slow progression of this disease. Here is the latest research on Inosine in PD.

September 15, 2021

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.

JAMA : the Journal of the American Medical Association
Parkinson Study Group SURE-PD3 InvestigatorsTiago A Mestre
September 10, 2021
Review
Open Access

Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor?

Frontiers in Neuroscience
Francisney Pinto NascimentoAdair R S Santos
August 27, 2021
Open Access

Synuclein Family Members Prevent Membrane Damage by Counteracting α-Synuclein Aggregation.

Biomolecules
Christian ScheibeKarin Hauser
July 6, 2021
Open Access

Poly (ADP-ribose) Interacts With Phosphorylated α-Synuclein in Post Mortem PD Samples.

Frontiers in Aging Neuroscience
Laura N PuentesRobert H Mach
May 26, 2021
Preprint
Open Access

Tannic Acid Inhibits α-Synuclein Amyloid Fibril Formation via Binding to the Monomer N-terminal Domain

BioRxiv : the Preprint Server for Biology
J. StoeberJean Baum
May 20, 2021

MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration.

Nature
Roberto SimoneRohan de Silva
May 6, 2021
Review

NMR illuminates intrinsic disorder.

Current Opinion in Structural Biology
H Jane Dyson, Peter E Wright
May 5, 2021

Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease.

Movement Disorders : Official Journal of the Movement Disorder Society
Tiago A MestreParkinson Study Group SURE-PD3 Investigators
April 28, 2021

NMR unveils an N-terminal interaction interface on acetylated-α-synuclein monomers for recruitment to fibrils.

Proceedings of the National Academy of Sciences of the United States of America
Xue YangJean Baum
February 11, 2021
Review

Fluorescence-based techniques for the detection of the oligomeric status of proteins: implication in amyloidogenic diseases.

European Biophysics Journal : EBJ
Lipika Mirdha, Hirak Chakraborty
January 24, 2021
Preprint
Open Access

Molecular basis of small-molecule binding to α-synuclein

BioRxiv : the Preprint Server for Biology
P. RobustelliDavid E. Shaw
January 23, 2021
Open Access

The Localization of Alpha-synuclein in the Endocytic Pathway.

Neuroscience
Mohammad A A FakhreeMireille M A E Claessens
December 23, 2020
Open Access

Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD).

Annals of Clinical and Translational Neurology
Ruth B SchneiderParkinson Study Group AT-HOME PD Investigators
December 4, 2020

Lipid-Chaperone Hypothesis: A Common Molecular Mechanism of Membrane Disruption by Intrinsically Disordered Proteins.

ACS Chemical Neuroscience
Michele F. M. SciaccaCarmelo La Rosa
August 23, 2020
Open Access

The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin.

Biomolecules
Line K SkaanningBirthe B Kragelund
August 7, 2020
Preprint
Open Access

The Lipid-Chaperon Hypothesis: A Common Molecular Mechanism of Membrane Disruption by Intrinsically Disordered Proteins

ChemRxiv
Michele F. M. SciaccaCarmelo La Rosa

Sign up to follow this feed and discover related papers.

Related Feeds

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Alpha-Synuclein Structure & Function

α-Synuclein is an integral component of Lewy bodies which are comprised of protein clumps and are a pathological hallmark of Parkinson’s disease. Here is the latest research on α-synuclein structure and function.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

© 2021 Meta ULC. All rights reserved
/feed-previews/inosine-parkinsons-disease/802045dd-a370-4152-9fdc-c13481caa2f4